As cyclin D1 ablation attenuates tumor growth and activation of cellular senescence, therapeutic targeting of cyclin D1‐associated CDK activity may be therapeutically useful in human cancers (Y. J. Choi et al., 2012). This evidence concerns the gene CCND1 and neoplasm.